Your browser doesn't support javascript.
ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants.
Seow, Jeffrey; Graham, Carl; Hallett, Sadie R; Lechmere, Thomas; Maguire, Thomas J A; Huettner, Isabella; Cox, Daniel; Khan, Hataf; Pickering, Suzanne; Roberts, Rebekah; Waters, Anele; Ward, Christopher C; Mant, Christine; Pitcher, Michael J; Spencer, Jo; Fox, Julie; Malim, Michael H; Doores, Katie J.
  • Seow J; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Graham C; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Hallett SR; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Lechmere T; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Maguire TJA; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Huettner I; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Cox D; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Khan H; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Pickering S; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Roberts R; Harrison Wing, Guy's and St Thomas' NHS Trust, London, UK.
  • Waters A; Harrison Wing, Guy's and St Thomas' NHS Trust, London, UK.
  • Ward CC; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Mant C; Infectious Diseases Biobank, Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Pitcher MJ; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Spencer J; Peter Gorer Department of Immunobiology, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Fox J; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK; Harrison Wing, Guy's and St Thomas' NHS Trust, London, UK.
  • Malim MH; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK.
  • Doores KJ; Department of Infectious Diseases, School of Immunology and Microbial Sciences, King's College London, London, UK. Electronic address: katie.doores@kcl.ac.uk.
Cell Rep ; 39(5): 110757, 2022 05 03.
Article in English | MEDLINE | ID: covidwho-1850799
ABSTRACT
Although the antibody response to COVID-19 vaccination has been studied extensively at the polyclonal level using immune sera, little has been reported on the antibody response at the monoclonal level. Here, we isolate a panel of 44 anti-SARS-CoV-2 monoclonal antibodies (mAbs) from an individual who received two doses of the ChAdOx1 nCoV-19 (AZD1222) vaccine at a 12-week interval. We show that, despite a relatively low serum neutralization titer, Spike-reactive IgG+ B cells are still detectable 9 months post-boost. Furthermore, mAbs with potent neutralizing activity against the current SARS-CoV-2 variants of concern (Alpha, Gamma, Beta, Delta, and Omicron) are present. The vaccine-elicited neutralizing mAbs form eight distinct competition groups and bind epitopes overlapping with neutralizing mAbs elicited following SARS-CoV-2 infection. AZD1222-elicited mAbs are more mutated than mAbs isolated from convalescent donors 1-2 months post-infection. These findings provide molecular insights into the AZD1222 vaccine-elicited antibody response.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Rep Year: 2022 Document Type: Article Affiliation country: J.celrep.2022.110757

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Rep Year: 2022 Document Type: Article Affiliation country: J.celrep.2022.110757